// App-Quantinova.ai

: Safety of Dabigatran Etexilate for Secondary Prevention of Venous Thromboembolism in Paediatric Patient

Researchers

Presenter

  • L. Brandao

Principal Investigators

  • M. Albisetti

  • J. Halton

  • L. Bomgaars

  • E. Chalmers

  • L. Mitchell

  • I. Nurmeev

  • P. Svirin

  • T. Kuhn

  • O. Zapletal

  • I. Tartakovsky

  • M. Simetzberger

  • F. Huang

  • Z. Sun

  • S. Gropper

  • M. Brueckmann

  • M. Luciani

Medical Centers

  • Hospital for Sick Children, Toronto, ON, Canada

  • University Childrens Hospital, Zurich, Switzerland

  • Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada,

  • Texas Children's Cancer Center, Baylor College of Medicine, Department of Pediatrics, Houston, United States

  • Royal Hospital for Sick Children, Glasgow, United Kingdom

  • Pediatric Hospital, Kazan, Republic Tatarstan, Russian Federation

  • Morozovskaya Children Hospital, Pediatric Hematology, Moscow, Russian Federation

  • University Hospital Ostrava, Pediatric Hematology/Oncology, Ostrava‐ Poruba, Czech Republic

  • University Hospital Brno, Pediatric Hematology, Brno, Czech Republic

  • Boehringer Ingelheim International GmbH, Therapeutic Area Cardiovascular Medicine, Ingelheim am Rhein, Germany

  • Boehringer Ingelheim RCV GmbH & Co. KG, Department of Clinical Development, Wien, Austria

  • Boehringer Ingelheim Pharmaceuticals, Inc, Translational Medicine and Clinical Pharmacology, Ridgefield, United States

  • Pediatric Hospital Bambino Gesù, Pediatric Hematology/Oncology, Rome, Italy

Locations

  • Canada

  • Switzerland

  • United States

  • United Kingdom

  • Russia

  • Czech Republic

  • Germany

  • Austria

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Pradax

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Prospective

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved